先進治療薬CDMO市場：製品、フェーズ、適応症、エンドユーザー別-2025-2030年世界予測

先進治療薬CDMO市場は、2023年に75億4,000万米ドルと評価され、2024年には87億4,000万米ドルに達すると予測され、CAGR 17.06%で成長し、2030年には227億4,000万米ドルに達すると予測されています。

先進治療薬（ATMP）の開発・製造受託機関（CDMO）は、バイオテクノロジーや製薬分野で極めて重要な役割を果たしており、遺伝子治療、細胞治療、組織工学製品などの革新的な治療法の開発・製造に不可欠なサービスを提供しています。ATMPの必要性は、個別化医療に対する需要の高まりと、そうでなければ不治の病に対する治療の進歩によって強調されており、腫瘍学、希少疾患、神経学、再生医療における用途と最終用途の範囲を飛躍的に拡大しています。この市場の主な成長要因としては、細胞加工における技術的進歩、臨床試験プロジェクトの増加、製品承認プロセスを迅速化する有利な規制枠組みなどが挙げられます。しかし、スケーラブルな製造プロセスや自動化技術の強化には潜在的な機会が残されています。こうした機会を生かすためには、ナノスケールのソリューションや生産分析のためのデジタル・インフラに焦点を当てたバイオテクノロジー企業とのパートナーシップを促進するための投資が不可欠となる可能性があります。とはいえ、市場の成長には、製造コストの高さ、規制要件の厳しさ、熟練労働力の不足といった課題があり、これらは治療薬のタイムリーな生産と供給に影響を及ぼす可能性があります。さらに、サプライチェーンの複雑さや多くのATMP技術の初期段階といった制約が、さらなる障害となっています。技術革新と研究の最良の道は、バイオリアクター技術の向上、遺伝子編集ツールの改善、ATMPの安定性と流通を支えるコールドチェーン物流の最適化であろう。学術機関やバイオテクノロジー・イノベーターとの連携を重視することも、技術的ブレークスルーを促進する可能性があります。市場はダイナミックで、治療法の進歩と技術的強化の双方に根ざした高い成長の可能性を秘めているが、競争力を維持し市場シェアを最大化するためには、規制や物流の課題を戦略的に乗り越える必要があります。

市場力学：急速に進化する先進治療薬CDMO市場の主要市場インサイトを公開

先進治療薬CDMO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 新規感染症の出現に伴う希少疾患の急増
  • 先端治療薬開発のための臨床試験件数の増加
  • 世界の医薬品研究開発投資の増加
• 市場抑制要因
  • ATMPソリューションのアウトソーシングに伴う高コスト
• 市場機会
  • 先端治療薬CDMOによる先端技術の採用
  • 先端治療薬の研究開発のための戦略的提携と拡大活動
• 市場の課題
  • ATMPの承認と商業化に関する政府の厳しい規則と規制

ポーターのファイブフォース：先進治療薬CDMO市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：先進治療薬CDMO市場における外部からの影響の把握

外部マクロ環境要因は、先進治療薬CDMO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析先進治療薬CDMO市場における競合情勢の把握

先進治療薬CDMO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス先進治療薬CDMO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、先進治療薬CDMO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨先進治療薬CDMO市場における成功への道筋を描く

先進治療薬CDMO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 希少疾患の蔓延と新規疾患の出現の増加

感染症

• 先進治療薬開発のための臨床試験の増加
• 世界中で医薬品研究開発への投資が増加
• 抑制要因
  • ATMPソリューションのアウトソーシングに伴う高コスト
• 機会
  • 先進的な治療薬による先進技術の採用

製品 CDMO

• 先端治療薬の研究開発のための戦略的提携と拡大活動
• 課題
  • ATMPの承認と

商業化

• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 先進治療薬CDMO市場：製品別

• 細胞療法
• 遺伝子治療
• 組織工学

第7章 先進治療薬CDMO市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII
• フェーズIV

第8章 先進治療薬CDMO市場適応症別

• 心臓病学
• 中枢神経系
• 皮膚科
• 内分泌、代謝、遺伝
• 消化器内科
• 血液学
• 免疫学と炎症
• 感染症
• 筋骨格
• 腫瘍学
• 眼科

第9章 先進治療薬CDMO市場：エンドユーザー別

• 学術調査機関
• バイオテクノロジーおよび製薬会社
• 臨床調査機関（CRO）
• 病院と診療所

第10章 南北アメリカの先進治療薬CDMO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の先進治療薬CDMO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの先進治療薬CDMO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abzena
• Advanced Therapies, Inc. by WuXi AppTec
• AGC Inc.
• Aldevron
• Almac Group
• Arranta Bio Holdings, LLC
• Bio Elpida
• BlueReg
• Catalent Inc.
• CELONIC Group
• CGT Catapult
• Charles River Laboratories International, Inc.
• Coriolis Pharma Research GmbH
• Eurofins Scientific SE
• FUJIFILM Corporation
• Lonza Group
• Minaris Regenerative Medicine
• Oxford Biomedica PLC
• Patheon by Thermo Fisher Scientific Inc.
• Rentschler Biopharma SE
• REPROCELL Inc.
• RoslinCT
• Samsung Biologics
• VIVEBIOTECH S.L.

LIST OF FIGURES

• FIGURE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET RESEARCH PROCESS
• FIGURE 2. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET DYNAMICS
• TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ENDOCRINE, METABOLIC, GENETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 68. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 69. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 72. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 73. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 74. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 141. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 142. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 143. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 157. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 158. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 159. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 161. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 162. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 163. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 201. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 202. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

The Advanced Therapy Medicinal Products CDMO Market was valued at USD 7.54 billion in 2023, expected to reach USD 8.74 billion in 2024, and is projected to grow at a CAGR of 17.06%, to USD 22.74 billion by 2030.

Advanced Therapy Medicinal Products (ATMPs) Contract Development and Manufacturing Organizations (CDMOs) play a pivotal role in the biotechnology and pharmaceutical sectors, offering essential services in the development and production of innovative therapies such as gene therapies, cell therapies, and tissue-engineered products. The necessity for ATMPs is underscored by the rising demand for personalized medicine and the advancement of treatments for otherwise incurable diseases, which has exponentially driven the application and end-use scope within oncology, rare diseases, neurology, and regenerative medicine. Key growth influencers in this market include technological advancements in cell processing, an increasing number of clinical trial projects, and favorable regulatory frameworks that expedite product approval processes. However, potential opportunities remain within the enhancement of scalable manufacturing processes and automation technologies. To capitalize on these opportunities, investment in facilitating partnerships with biotech firms focusing on nanoscale solutions and digital infrastructure for production analytics could be vital. Nonetheless, market growth is challenged by high manufacturing costs, stringent regulatory requirements, and a shortage of skilled workforce which may impact timely production and delivery of therapies. Moreover, limitations such as supply chain complexities and the nascent stage of many ATMP technologies create further obstacles. The best avenues for innovation and research could be in enhancing bioreactor technologies, improving gene editing tools, and optimizing cold chain logistics to support the stability and distribution of ATMPs. Emphasizing collaborations with academic institutions and biotech innovators may also drive technological breakthroughs. The market is dynamic, with high growth potential rooted in both therapeutic advancements and technological augmentations, but necessitates strategic navigation through regulatory and logistical challenges to sustain competitive leverage and maximize market share.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Advanced Therapy Medicinal Products CDMO Market

The Advanced Therapy Medicinal Products CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Proliferation in prevalence of rare diseases with growing emergence of novel infectious diseases
  • Rising numbers of clinical trials for development of advanced therapy medicinal products
  • Increasing investments in pharmaceutical research and development worldwide
• Market Restraints
  • High cost associated with outsourcing ATMP solutions
• Market Opportunities
  • Adoption of advanced technologies by advanced therapy medicinal products CDMOs
  • Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
• Market Challenges
  • Stringent governmental rules and regulations for ATMP approvals and commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Advanced Therapy Medicinal Products CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Advanced Therapy Medicinal Products CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Advanced Therapy Medicinal Products CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Advanced Therapy Medicinal Products CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Advanced Therapy Medicinal Products CDMO Market

A detailed market share analysis in the Advanced Therapy Medicinal Products CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Advanced Therapy Medicinal Products CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Advanced Therapy Medicinal Products CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Advanced Therapy Medicinal Products CDMO Market

A strategic analysis of the Advanced Therapy Medicinal Products CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..

Market Segmentation & Coverage

This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Products, market is studied across Cell Therapy, Gene Therapy, and Tissue Engineered.
• Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
• Based on Indication, market is studied across Cardiology, Central Nervous System, Dermatology, Endocrine, Metabolic, Genetic, Gastroenterology, Hematology, Immunology & Inflammation, Infectious Disease, Musculoskeletal, Oncology, and Ophthalmology.
• Based on End-Users, market is studied across Academic and Research Institutions, Biotechnology & Pharmaceutical Companies, Clinical Research Organizations (CROs), and Hospitals and Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Proliferation in prevalence of rare diseases with growing emergence of novel

infectious diseases

• 5.1.1.2. Rising numbers of clinical trials for development of advanced therapy medicinal products
• 5.1.1.3. Increasing investments in pharmaceutical research and development worldwide
• 5.1.2. Restraints
  • 5.1.2.1. High cost associated with outsourcing ATMP solutions
• 5.1.3. Opportunities
  • 5.1.3.1. Adoption of advanced technologies by advanced therapy medicinal

products CDMOs

• 5.1.3.2. Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
• 5.1.4. Challenges
  • 5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and

commercialization

• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Advanced Therapy Medicinal Products CDMO Market, by Products

• 6.1. Introduction
• 6.2. Cell Therapy
• 6.3. Gene Therapy
• 6.4. Tissue Engineered

7. Advanced Therapy Medicinal Products CDMO Market, by Phase

• 7.1. Introduction
• 7.2. Phase I
• 7.3. Phase II
• 7.4. Phase III
• 7.5. Phase IV

8. Advanced Therapy Medicinal Products CDMO Market, by Indication

• 8.1. Introduction
• 8.2. Cardiology
• 8.3. Central Nervous System
• 8.4. Dermatology
• 8.5. Endocrine, Metabolic, Genetic
• 8.6. Gastroenterology
• 8.7. Hematology
• 8.8. Immunology & Inflammation
• 8.9. Infectious Disease
• 8.10. Musculoskeletal
• 8.11. Oncology
• 8.12. Ophthalmology

9. Advanced Therapy Medicinal Products CDMO Market, by End-Users

• 9.1. Introduction
• 9.2. Academic and Research Institutions
• 9.3. Biotechnology & Pharmaceutical Companies
• 9.4. Clinical Research Organizations (CROs)
• 9.5. Hospitals and Clinics

10. Americas Advanced Therapy Medicinal Products CDMO Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abzena
• 2. Advanced Therapies, Inc. by WuXi AppTec
• 3. AGC Inc.
• 4. Aldevron
• 5. Almac Group
• 6. Arranta Bio Holdings, LLC
• 7. Bio Elpida
• 8. BlueReg
• 9. Catalent Inc.
• 10. CELONIC Group
• 11. CGT Catapult
• 12. Charles River Laboratories International, Inc.
• 13. Coriolis Pharma Research GmbH
• 14. Eurofins Scientific SE
• 15. FUJIFILM Corporation
• 16. Lonza Group
• 17. Minaris Regenerative Medicine
• 18. Oxford Biomedica PLC
• 19. Patheon by Thermo Fisher Scientific Inc.
• 20. Rentschler Biopharma SE
• 21. REPROCELL Inc.
• 22. RoslinCT
• 23. Samsung Biologics
• 24. VIVEBIOTECH S.L.